Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;36(9):1826-1831.
doi: 10.1038/s41433-022-02090-7. Epub 2022 May 13.

Evaluation of the choroidal vascularity index after subthreshold yellow laser treatment in the patients with chronic central serous chorioretinopathy

Sema Tamer Kaderli  1 , Aylin Karalezli  2 , Ahmet Kaderli  2 , Simay Can Taskin  2 , Sabahattin Sul  2
Affiliations

Evaluation of the choroidal vascularity index after subthreshold yellow laser treatment in the patients with chronic central serous chorioretinopathy

Sema Tamer Kaderli et al. Eye (Lond). 2022 Sep.

Abstract

Purpose: To assess the choroidal vascularity index (CVI) after subthreshold laser treatment in patients with central serous chorioretinopathy (CSC).

Method: A total of 32 eyes with CSC were included in this study. In group 1, 14 eyes with persistent CSC were treated with the PASCAL (Endpoint Management Software) at 577-nm wavelength and in group 2, 18 eyes without treatment. The luminal area (LA), stromal area (SA), total area of choroid (TA), and CVI were measured by binarization (ImageJ) of optical coherence tomography images. Changes of choroidal structure parameters were evaluated over 3 months.

Result: A significant decrease was observed in LA, TA, and CVI at the third month after the laser treatment (p = 0.018, p = 0.024, p = 0.046). The best-corrected visual acuity (BCVA) and choriocapillaris plexus (CCP) flow area values were increased after treatment in group 1 (p < 0.001, p = 0.002). The final subfoveal fluid height, and CVI were lower in group 1 (p = 0.003, p = 0.011). The visual acuity and CCP flow area were higher in group 1 at the third month (p < 0.001, p = 0.003). A positive correlation between the final BCVA and CVI was observed (r = 0.539, p = 0.01).

Discussion: Decreased CVI was observed in CSC eyes after subthreshold yellow laser treatment. The CVI may be a useful index to evaluate the response to treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Enhanced depth imaging mode of spectral domain optical coherence tomography scan and OCTA image for CCP flow area.
A Sampling of CVI calculation via ImageJ software on EDI-OCT image. The yellow outlines expressed the luminal area applying the color threshold tool. B CCP flow area image with 3 mm circular area via OCTA.
See this image and copyright information in PMC

References

    1. Piccolino FC, de la Longrais RR, Ravera G, Eandi CM, Ventre L, Abdollahi A, et al. The foveal photoreceptor layer and visual acuity loss in central serous chorioretinopathy. Am J Ophthalmol. 2005;139:87–99. doi: 10.1016/j.ajo.2004.08.037. - DOI - PubMed
    1. Bae SH, Heo JW, Kim C, Kim TW, Lee JY, Song SJ, et al. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol. 2011;152:784–92.e782. doi: 10.1016/j.ajo.2011.04.008. - DOI - PubMed
    1. Iovino C, Au A, Chhablani J, Parameswarappa DC, Rasheed MA, Cennamo G, et al. Choroidal anatomic alterations after photodynamic therapy for chronic central serous chorioretinopathy: a multicenter study. Am J Ophthalmol. 2020;217:104–13. doi: 10.1016/j.ajo.2020.04.022. - DOI - PubMed
    1. Gupta B, Elagouz M, McHugh D, Chong V, Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin Exp Ophthalmol. 2009;37:801–5. doi: 10.1111/j.1442-9071.2009.02157.x. - DOI - PubMed
    1. Lavinsky D, Wang J, Huie P, Dalal R, Lee SJ, Lee DY, et al. Nondamaging retinal laser therapy: rationale and applications to the macula. Invest Ophthalmol Vis Sci. 2016;57:2488–500. doi: 10.1167/iovs.15-18981. - DOI - PMC - PubMed